Is Concentra Group Holdings (CON) overvalued or fairly valued?

MarketChacha shows Concentra Group Holdings's valuation in context — a trailing P/E of about 23.7, a forward P/E of about 21.1, a price-to-book of about 10.4 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Concentra Group Holdings's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.54×) from reported figures — education, not a rating.

What is Concentra Group Holdings's revenue?

Concentra Group Holdings reported revenue of $2.2B for FY2025, with net profit of $166.4M, per official filings.

What is the share price of Concentra Group Holdings (CON)?

Concentra Group Holdings last traded at $38.68 (+1.3% on the day), as of 10/20/2026 — a delayed quote shown for education, not investment advice.

Concentra Group Holdings

CON · NYSE · Healthcare · United States

Snapshot

TickerCON

ExchangeNYSE

SectorHealthcare

IndustryMedical Care Facilities

CountryUnited States

Employees9,967

HeadquartersAddison, United States

Websitewww.concentra.com

Filings tracked18

About Concentra Group Holdings

Concentra Group Holdings Parent, Inc. provides occupational health services in the United States. The company operates in three segments: Occupational Health centers, Onsite health clinics, and Other business. It offers occupational health services, including workers compensation, employer, and consumer health services; and employer-sponsored primary care services at workplace, including mobile health and episodic specialty testing services. It also operates Concentra Telemed, a telemedicine platform for the treatment of work-related injuries and illnesses; Concentra Pharmacy for distributing repackaged medications; and Concentra Medical Compliance Administration, a third-party administrator that helps to manage abuse testing programs for employers with regulated or non-regulated workforces. In addition, the company provides injury care, primary care, urgent care, preventive care, clinical testing, physical examinations and evaluations, drug and alcohol screenings, clinical testing, vaccinations and other preventive care, and a range of consultative services designed to protect employees from workplace hazards. The company was founded in 1979 and is based in Addison, Texas.

Who owns it

Insiders9.6%
Institutions90.4%
Public & other0.0%

407 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.13.92%
Price (T.Rowe) Associates Inc13.89%
Vanguard Portfolio Management LLC5.35%
Vanguard Capital Management LLC4.02%
State Street Corporation3.80%
Jennison Associates LLC2.55%
Dimensional Fund Advisors LP2.53%
Geode Capital Management, LLC2.43%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Margin has compressed by about 2.1 points over the period — profitability is trending down.

Cash conversion1.54×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend9.8% → 7.7%

Margin has compressed by about 2.1 points over the period — profitability is trending down.

Return on equity42.3%

Latest ROE of 42.3% — capital is generating a healthy return.

Growth qualityrev 8% · PAT -4%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $571.6M · EPS 0.29

Est. earnings growth +3.5%

Next fiscal year

Rev $2.5B · EPS 1.84

Est. earnings growth +11.7%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$2.2B

Net margin

7.7%

ROE

42.3%

Revenue CAGR (2y)

+8.5%

Profit CAGR (2y)

-3.8%

EPS (FY2025)

1.30

Net profit (FY2025)

$166.4M

Ask MarketChacha about CON

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$2.2B	$166.4M	1.30	7.7%	42.3%
FY2024	$1.9B	$166.5M	1.46	8.8%	60.4%
FY2023	$1.8B	$179.9M	1.73	9.8%	—

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$606.0M	$65.3M	0.51	10.8%
2026Q1	$569.6M	$50.5M	0.39	8.9%
2025Q3	$572.8M	$48.3M	0.38	8.4%
2025Q2	$550.8M	$44.6M	0.35	8.1%
2025Q1	$500.8M	$38.9M	0.30	7.8%
2024Q3	$489.6M	$44.3M	0.37	9.1%
2024Q2	$477.9M	$51.7M	0.50	10.8%
2024Q1	$467.6M	$49.0M	0.47	10.5%
2023Q3	$474.0M	$53.1M	0.51	11.2%
2023Q2	$467.1M	$52.7M	0.51	11.3%
2023Q1	—	$46.3M	—	—

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC9/8/2026material
8-K — Material agreement, Exhibits
SEC8/27/2026material
8-K — Results of operations, Executive/director change, Reg FD disclosure, Other events, Exhibits
SEC8/6/2026material
10-Q filing
SEC8/6/2026
8-K — Executive/director change, Exhibits
SEC7/10/2026material
8-K — Results of operations, Reg FD disclosure, Other events, Exhibits
SEC5/7/2026material
10-Q filing
SEC5/7/2026
8-K — Shareholder vote results
SEC4/30/2026material
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC4/14/2026material
8-K — Results of operations, Reg FD disclosure, Other events, Exhibits
SEC2/26/2026material
10-K filing
SEC2/26/2026
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC1/28/2026material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC1/12/2026material

2025

8-K — Executive/director change
SEC11/10/2025material
8-K — Results of operations, Reg FD disclosure, Other events, Exhibits
SEC11/6/2025material
10-Q filing
SEC11/6/2025
8-K — Results of operations, Reg FD disclosure, Other events, Exhibits
SEC8/7/2025material
10-Q filing
SEC8/7/2025

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.